Lidocaine inhibits osteoclast activity in vitro

Bone Reports · Published 2026-07-11 · DOI 10.1016/j.bonr.2026.101935

Free full text

Authors (3)

Stan Tuijp, Marc Meijer, Ineke D.C. Jansen

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Tuijp, S., Meijer, M., Jansen, I. (2026). Lidocaine inhibits osteoclast activity in vitro. Bone Reports. https://doi.org/10.1016/j.bonr.2026.101935

Related articles

• Predictors of clinically meaningful bone mineral density gains with romosozumab: An explainable machine leaning analysis of a real-world cohort · Bone Reports · 2025 · Same journal
• Transferrin-dependent uptake and distribution of iron in osteoclast-like cells · Bone Reports · 2026 · Same journal
• Effectiveness of romosozumab following prior raloxifene treatment in primary osteoporosis: An observational study · Bone Reports · 2026 · Same journal
• Integrating intrinsic musculoskeletal pathology and genetics: Recent advances in unravelling the causative factors of adolescent idiopathic scoliosis · Bone Reports · 2025 · Same journal
• Simulated microgravity accurately models long-duration spaceflight effects on bone and skeletal muscle in skeletally immature mice · Bone Reports · 2025 · Same journal
• Intelligent identification of osteoporosis on hip X-rays using vision transformer · Bone Reports · 2026 · Same journal
• A comparative analysis of bone mineral density in cerebral palsy and spinal muscular atrophy · Bone Reports · 2025 · Same journal
• Individualized antiresorptive therapy in fibrous dysplasia and McCune-Albright syndrome: A retrospective cohort study · Bone Reports · 2026 · Same journal
• Cyclin-dependent kinase inhibitor-1 deficiency enhances bone destruction in a mouse model of arthritis · Bone Reports · 2025 · Same journal
• Sost deficiency leads to greater bone vascular porosity, but similar osteocyte lacunar properties with increasing age · Bone Reports · 2026 · Same journal